---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-004403"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:19:43.054821+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Adicet Bio posts updated corporate presentation highlighting allogeneic CAR γδ1 cell therapies

## Summary
- Presentation dated January 16, 2024 posted to investor.adicetbio.com.
- Focus on allogeneic CAR γδ1 cell therapies for autoimmune diseases and cancer.
- No clinical data, financial updates, or pipeline milestones disclosed in the filing.

## SEC filing metadata
- accession: 0000950170-24-004403
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024004403/0000950170-24-004403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024004403/acet-20240116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-004403
- JSON: https://secwatch.observer/filing/0000950170-24-004403.json
- Plain text: https://secwatch.observer/filing/0000950170-24-004403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.